These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36495880)

  • 41. Ustekinumab associated with flares of psoriatic arthritis.
    Stamell EF; Kutner A; Viola K; Cohen SR
    JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M; Joseph GJ; Princic N; Harrison DJ
    J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-field MRI and powerdoppler sonography: supplementary imaging, techniques in assessing disease activity in patients with psoriasis arthritis (PsA) and rheumatoid arthritis (RA) receiving adalimumab.
    Hoehle M
    Rheumatol Int; 2013 Feb; 33(2):545-6. PubMed ID: 22138673
    [No Abstract]   [Full Text] [Related]  

  • 44. The next quantum leap forward? Bimekizumab for psoriasis.
    Huang WW; Feldman SR
    Lancet; 2021 Feb; 397(10273):446-448. PubMed ID: 33549176
    [No Abstract]   [Full Text] [Related]  

  • 45. Injection Site Reactions to Biologic Agents Used in Psoriasis and Psoriatic Arthritis.
    Henderson Berg MH; Carrasco D
    J Drugs Dermatol; 2017 Jul; 16(7):695-698. PubMed ID: 28697222
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Paradoxical Pustular Psoriasis in a Patient With Psoriatic Arthritis on Secukinumab Treatment.
    Abbruzzese A; Venerito V; Lopalco G; Fornaro M; Giannotta M; Iannone F
    J Clin Rheumatol; 2020 Sep; 26(6):e208-e209. PubMed ID: 31192857
    [No Abstract]   [Full Text] [Related]  

  • 47. Efficacy of secukinumab in psoriasis and psoriatic arthritis: A retrospective multicentre study.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Galán-Gutierrez M; Martinez-Pilar L
    Med Clin (Barc); 2020 May; 154(9):370-371. PubMed ID: 30717997
    [No Abstract]   [Full Text] [Related]  

  • 48. Ustekinumab: a review of its use in psoriatic arthritis.
    McKeage K
    Drugs; 2014 Jun; 74(9):1029-39. PubMed ID: 24919864
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ustekinumab for psoriatic arthritis: close to the PSUMMIT?
    Warren RB; Chinoy H
    Lancet; 2013 Aug; 382(9894):748-9. PubMed ID: 23769295
    [No Abstract]   [Full Text] [Related]  

  • 50. Treatment of psoriatic arthritis with secukinumab: a case series.
    Nicola S; Rolla G; Monti R; Brussino L
    J Dermatolog Treat; 2018; 29(sup1):6-8. PubMed ID: 30247936
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real-world biologic and apremilast treatment patterns in patients with psoriasis and psoriatic arthritis.
    Feldman SR; Zhang J; Martinez DJ; Lopez-Gonzalez L; Hoit Marchlewicz E; Shrady G; Zhao Y; Mendelsohn AM
    Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755976
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic Study.
    Ballegaard C; Jørgensen TS; Skougaard M; Strand V; Mease PJ; Kristensen LE; Dreyer L; Gottlieb A; de Wit M; Christensen R; Tarp S
    Arthritis Care Res (Hoboken); 2018 Aug; 70(8):1206-1217. PubMed ID: 29073353
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Malignancies developing in obese patients with psoriasis while on antitumour necrosis factor-α therapies: a case series.
    Sadlier M; Lally A; Kirby B
    Br J Dermatol; 2012 Oct; 167(4):937-8. PubMed ID: 22428935
    [No Abstract]   [Full Text] [Related]  

  • 54. Paradoxical psoriatic arthritis in a patient with psoriasis treated with guselkumab.
    Carriero A; Lubrano E; Picerno V; Padula AA; D'Angelo S
    Clin Exp Dermatol; 2022 Apr; 47(4):783-785. PubMed ID: 34905263
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful use of tocilizumab in a patient with psoriatic arthritis.
    Hughes M; Chinoy H
    Rheumatology (Oxford); 2013 Sep; 52(9):1728-9. PubMed ID: 23424264
    [No Abstract]   [Full Text] [Related]  

  • 56. Ustekinumab for psoriatic arthritis.
    Cuchacovich RS; Espinoza LR
    Lancet; 2009 Feb; 373(9664):605-6. PubMed ID: 19217153
    [No Abstract]   [Full Text] [Related]  

  • 57. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
    Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
    Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis.
    van de Kerkhof PCM
    Br J Dermatol; 2021 Nov; 185(5):879. PubMed ID: 34402525
    [No Abstract]   [Full Text] [Related]  

  • 60. Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis.
    Reich K; Baraliakos X; Coates LC; Elewski B; Bao W; Kasparek T; Gaillez C; Pournara E; Aassi M; Perella C; Gottlieb AB
    Br J Dermatol; 2022 Sep; 187(3):438-441. PubMed ID: 35257363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.